

Annexure XIX

To,
Manager - Listing Compliance
National Stock Exchange of India Limited
'Exchange Plaza'. C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Dear Sir,

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the Composite Scheme of Amalgamation (Merger by Absorption) cum Demerger and Arrangement presented under Sections 230 to 232 read with Section 66 and other applicable provisions of Companies Act, 2013 ('the Act') amongst Hydra Active Pharma Sciences Private Limited ("Hydra" or the "Amalgamating Company 1" or "Transferor Company 1") and Aurore Life Sciences Private Limited ("Aurore Life Sciences" or the "Amalgamated Company 1" or "Transferee Company 1" or "Demerged Company") and Emphyrean Lifesciences Private Limited ("Emphyrean" or the "Amalgamating Company 2" or "Transferor Company 2") and Solara Active Pharma Sciences Limited ("Solara" or the "Company" or "Amalgamated Company 2" or "Transferee Company 2" or "Resulting Company") and their respective shareholders (the "Scheme").

In connection with the above application, we hereby confirm that no material event impacting the valuation has occurred during the intervening period of filing the scheme documents with Stock Exchange and period under consideration for valuation.

For Solara Active Pharma Sciences Limited,



S Murali Krishna
Company Secretary
Date: November 29, 2021

